scPharmaceuticals
scPharmaceuticals was a specialty biopharmaceutical company that developed and commercialized FUROSCIX, an FDA-approved On-body Infusor for subcutaneous furosemide delivery to treat fluid overload in heart failure patients. Acquired by MannKind Corporation for up to $360 million in August 2025.
- Company typePublic
- Founded2014
- HeadquartersLexington, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What scPharmaceuticals does
scPharmaceuticals Inc. was a specialty biopharmaceutical company founded in 2014 and headquartered in Lexington, Massachusetts, that developed and commercialized subcutaneous drug delivery products for chronic disease management. The company's core product is FUROSCIX, an FDA-approved On-body Infusor that delivers furosemide subcutaneously for the treatment of fluid overload (congestion) in heart failure patients who are not adequately controlled on oral diuretics. The underlying technology pairs a proprietary concentrated liquid furosemide formulation (protected by a pending patent on solubility-optimized compositions covering pH, excipients, and buffers) with a wearable delivery device that enables outpatient self-administration, providing an alternative to IV diuretic infusions delivered in clinical settings.
scPharmaceuticals firmographics
Firmographics- Name
- scPharmaceuticals
- Legal name
- scPharmaceuticals Inc.
- Website
- https://scpharmaceuticals.com
- Company type
- Public
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- scPharmaceuticals was a specialty biopharmaceutical company that developed and commercialized FUROSCIX, an FDA-approved On-body Infusor for subcutaneous furosemide delivery to treat fluid overload in heart failure patients. Acquired by MannKind Corporation for up to $360 million in August 2025.
- Ownership category
- akta.pro rank
scPharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals — Cardiology / Heart Failure
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Wearable Injectors & On-Body Delivery Systems (HLAHAIAE)
Keywords
Where scPharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Markets served
scPharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- FUROSCIX Product Sales: Revenue generated from sales of FUROSCIX (furosemide injection) delivered via the On-body Infusor for heart failure patients with fluid overload. The product was commercialized in the US market following FDA approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
scPharmaceuticals product offering
Product offeringCore offering
scPharmaceuticals develops and commercializes FUROSCIX, an on-body infusor that delivers subcutaneous furosemide for treatment of fluid overload (congestion) in heart failure patients, enabling outpatient administration as an alternative to IV diuretic infusions. The company also develops proprietary concentrated liquid furosemide formulations optimized for subcutaneous delivery. FUROSCIX is FDA-approved for adult and pediatric use, with a ReadyFlow Autoinjector sNDA under FDA review.
Product overview
scPharmaceuticals was a specialty pharmaceutical company focused on developing and commercializing subcutaneous drug delivery solutions for chronic diseases. The company's primary product was FUROSCIX, an on-body infusor that delivers furosemide subcutaneously for heart failure patients with fluid overload. scPharmaceuticals was acquired by MannKind Corporation in August 2025 for $360 million and is now operated as a wholly owned subsidiary, with FUROSCIX integrated into MannKind's cardiometabolic portfolio alongside Afrezza, V-Go, and Tyvaso DPI products.
Differentiator
Problem solved
Functional benefit
Brands
- FUROSCIX: On-body infusor for furosemide injection, a treatment for fluid overload in heart failure patients
Products and services
- FUROSCIX On-body Infusor (furosemide injection) An on-body infusor that delivers subcutaneous furosemide injection for treatment of fluid overload (congestion) in heart failure patients, enabling outpatient treatment without IV access. FDA-approved for adult use and, post-acquisition, for pediatric use.
Quantifiable outcome
- Reduced healthcare costs through outpatient treatment vs. IV clinic visits
- +1 more outcomes
Companies that use scPharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
scPharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
scPharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MannKind CorporationcoreMannKind Corporation acquired scPharmaceuticals for up to $360 million in August 2025 to expand its cardiometabolic treatment portfolio with FUROSCIX. scPharmaceuticals operates as a wholly owned subsidiary of MannKind. Blackstone provided strategic financing support for the acquisition.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
scPharmaceuticals competitors and assessment
Company assessmentDirect peers
- Insulet Corporation: Insulet's Omnipod is a body-worn, on-body infusion patch pump for subcutaneous drug delivery, the closest analog to the FUROSCIX On-body Infusor in wearable subcutaneous delivery technology. Both companies commercialize wearable injectors designed for patient self-administration outside clinical settings.
- Halozyme Therapeutics: Halozyme's ENHANZE platform enables high-volume subcutaneous delivery of therapeutics via recombinant hyaluronidase, directly addressing the same subcutaneous drug delivery problem FUROSCIX solves for furosemide. Both companies' core technology unlocks outpatient subcutaneous administration of drugs traditionally given intravenously.
- Enable Injections: Enable Injections develops large-volume wearable subcutaneous delivery devices (enFuse) that compete for the same outpatient subcutaneous infusion use case as the FUROSCIX On-body Infusor. Both companies target the same clinical value proposition of moving IV therapies into patient self-administered home settings.
- Cytokinetics: Cytokinetics develops cardiac myosin modulators (e.g., aficamten for HCM) for heart failure and related cardiovascular indications, addressing the same heart failure prescriber audience as FUROSCIX. Both companies target the cardiology channel for innovative therapies addressing cardiac dysfunction.
- Lexicon Pharmaceuticals: Lexicon developed sotagliflozin for heart failure and cardiorenal conditions, addressing the same heart failure and CKD populations targeted by FUROSCIX. Both companies pursued differentiated outpatient therapies for fluid management and cardiorenal outcomes.
Broad incumbents
- West Pharmaceutical Services: West Pharmaceutical is a leading provider of drug containment and delivery components including elastomeric stoppers, prefilled syringe systems, and wearable injector platforms serving the same pharmaceutical customers developing subcutaneous biologics and small molecules. Broad incumbent in injectable drug delivery infrastructure.
- Becton Dickinson: BD is a broad incumbent in drug delivery devices including prefilled syringes, autoinjectors, and wearable injection systems used across pharmaceutical customers. Its Pharmaceutical Systems segment competes with the FUROSCIX delivery approach as one of multiple portfolio offerings.
- AstraZeneca: AstraZeneca commercializes Farxiga (dapagliflozin) for heart failure with reduced and preserved ejection fraction, addressing the same HF patient population as FUROSCIX through an oral once-daily therapy. Broad incumbent in cardiovascular and cardiorenal therapeutics with established cardiology channel access.
Others
- United Therapeutics: United Therapeutics is a strategic partner of MannKind (Tyvaso DPI leverages MannKind's Technosphere platform) and operates in cardiopulmonary therapeutics including pulmonary hypertension and heart failure adjacencies, sharing commercial channels and ecosystem relationships relevant to FUROSCIX.
- MannKind Corporation: MannKind is the parent company that acquired scPharmaceuticals for $360M in August 2025 and now owns the FUROSCIX franchise. Not a comparable peer in market position but relevant as the operating umbrella for the asset and integrator of FUROSCIX with Afrezza, V-Go, and Tyvaso DPI.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
scPharmaceuticals social profiles
Digital presencescPharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
scPharmaceuticals leadership team
Management profileNumber of profiles
scPharmaceuticals funding detail
Funding detailFunding overview
Funding rounds8 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
scPharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about scPharmaceuticals
What does scPharmaceuticals do?
scPharmaceuticals develops and commercializes FUROSCIX, an on-body infusor that delivers subcutaneous furosemide for treatment of fluid overload (congestion) in heart failure patients, enabling outpatient administration as an alternative to IV diuretic infusions. The company also develops proprietary concentrated liquid furosemide formulations optimized for subcutaneous delivery. FUROSCIX is FDA-approved for adult and pediatric use, with a ReadyFlow Autoinjector sNDA under FDA review.
Is scPharmaceuticals a public or private company?
scPharmaceuticals is a public company. It is classified as corporate owned and is currently acquired.
When was scPharmaceuticals founded?
scPharmaceuticals was founded in 2014. It employs 101 to 250 people.
Where is scPharmaceuticals based?
scPharmaceuticals is headquartered in Lexington, United States, in the North America region.
How does scPharmaceuticals make money?
One revenue line is on record: FUROSCIX Product Sales.
Who are scPharmaceuticals's main competitors?
Direct peers on record are Insulet Corporation, Halozyme Therapeutics, Enable Injections, Cytokinetics and Lexicon Pharmaceuticals. Broad incumbents are West Pharmaceutical Services, Becton Dickinson and AstraZeneca. Others are United Therapeutics and MannKind Corporation.
Does scPharmaceuticals have an API?
No public API is recorded for scPharmaceuticals.
What industry is scPharmaceuticals in?
scPharmaceuticals's product category is Specialty Pharmaceuticals — Cardiology / Heart Failure. Its primary akta.pro industry code is HLAHAIAE, Wearable Injectors & On-Body Delivery Systems. Its NAICS code is 3391 and its SIC code is 3841.